Company: SUPN
Filing Date: 2025-06-16
Form Type: 8-K
Source: 0001104659-25-059687
Chunk: 6

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-06-16
Form: 8-K
Item: Item 8.01
Chunk 6
---
Item 8.01      Other Events.  

On June 16, 2025, the Company
issued a joint press release with Sage announcing the execution of the Merger Agreement and held an investor conference call. A copy of
the joint press release is filed as Exhibit 99.1 hereto, and the text of such joint press release is incorporated herein by reference.
A copy of the investor presentation presented on the conference call is filed as Exhibit 99.2 hereto and posted on the Company’s
website, and the text of such investor presentation is incorporated herein by reference.

Additional Information about the Tender Offer and Where to Find
It

The
tender offer for the outstanding common stock ofSage Therapeutics, Inc. (“ Sage”) has not been commenced. This filing
does not constitute a recommendation, an offer to purchase or a solicitation of an offer to sell Sage securities. At the time the tender
offer is commenced, Supernus Pharmaceuticals, Inc. (“ Supernus”) and Saphire Inc., a direct wholly owned subsidiary of Supernus
(“ Purchaser”), will file a Tender Offer Statement on Schedule TO (including an Offer to Purchase) with the Securities and
Exchange Commission (the “ SEC”) and thereafter, Sage will file a Solicitation/Recommendation Statement on Schedule 14D-9 with
the SEC, in each case, with respect to the tender offer. The solicitation and offer by Supernus to purchase shares of Sage common stock
will only be made pursuant to such Offer to Purchase and related materials. Once filed, investors and security holders are urged to read
these materials (including the Offer to Purchase, a related Letter of Transmittal and certain other tender offer documents, as each may
be amended or supplemented from time to time) carefully since they will contain important information that Sage investors and security
holders should consider before making any decision regarding tendering their common stock, including the terms and conditions of the tender
offer. The Tender Offer Statement, Offer to Purchase, Solicitation/Recommendation Statement and related materials will be filed with the
SEC, and Sage investors and security holders may obtain a free copy of these materials (when available) and other documents filed by Supernus,
Purchaser and Sage with the SEC at the website maintained by the SEC at www. sec. gov. In addition, the Tender Offer Statement and other
documents that Supernus and Purchaser file with the SEC will be made available to all investors and security holders of Sage free